Codice QR

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

Abstract Background MEK inhibitors (MEKi) were shown to be clinically insufficiently effective in patients suffering from BRAF wild-type (BRAF WT) melanoma, even if the MAPK pathway was constitutively activated due to mutations in NRAS or NF-1. Thus, novel combinations are needed to increase the eff...

Descrizione completa

Salvato in:
Autori principali: Francisco Meraz-Torres, Heike Niessner, Sarah Plöger, Simon Riel, Barbara Schörg, Nicolas Casadei, Manfred Kneilling, Martin Schaller, Lukas Flatz, Boris Macek, Thomas Eigentler, Olaf Rieß, Claus Garbe, Teresa Amaral, Tobias Sinnberg
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2024-01-01
Serie:Journal of Experimental & Clinical Cancer Research
Soggetti:
Melanoma
BRAF
Disulfiram
Trametinib
MEK inhibitor
ER stress
Accesso online:https://doi.org/10.1186/s13046-023-02941-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi